This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Performance dei guadagni passati

Il passato criteri di controllo 0/6

Atreca's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 11.8% annually.

Informazioni chiave

-14.6%

Tasso di crescita degli utili

51.1%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	-14.6%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-908.6%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2023

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come Atreca guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

DB:0C1 Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 23	-98	36	45
30 Jun 23	-85	38	51
31 Mar 23	-93	39	58
31 Dec 22	-97	39	62
30 Sep 22	-105	40	68
30 Jun 22	-110	41	70
31 Mar 22	-108	43	67
31 Dec 21	-109	43	67
30 Sep 21	-103	42	61
30 Jun 21	-98	42	59
31 Mar 21	-92	38	55
31 Dec 20	-86	37	52
30 Sep 20	-83	37	50
30 Jun 20	-76	33	48
31 Mar 20	-74	29	50
31 Dec 19	-67	24	49
30 Sep 19	-59	17	48
30 Jun 19	-53	13	43
31 Mar 19	-44	11	35
31 Dec 18	-38	9	31

Guadagni di qualità: 0C1 is currently unprofitable.

Margine di profitto in crescita: 0C1 is currently unprofitable.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: 0C1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerare la crescita: Unable to compare 0C1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: 0C1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).

Rendimento del capitale proprio

ROE elevato: 0C1 has a negative Return on Equity (-908.6%), as it is currently unprofitable.

This company listing is no longer active

Atreca Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day high: €16.00

New 90-day low: €10.50

New 90-day high: €13.60

New 90-day low - €10.50

New 90-day low - €12.70

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate